Journal
MICROORGANISMS
Volume 10, Issue 9, Pages -Publisher
MDPI
DOI: 10.3390/microorganisms10091764
Keywords
SARS-CoV-2; gut-lung axis; immunomodulation; probiotics; bacteriocins
Categories
Ask authors/readers for more resources
The human gastrointestinal tract ecosystem, known as gut microbiota, is extensively studied and is associated with various diseases. The interaction between gut and lung microbiota affects immune and inflammatory responses. COVID-19 disrupts gut microbiota, leading to increased inflammation and lung damage. Probiotics can modulate cytokine secretion, stimulate immune response, and inhibit NLRP3 inflammasome activation in COVID-19 infection.
The ecosystem of the human gastrointestinal tract, named gut microbiota, represents the most thoroughly mapped ecosystem. Perturbations on bacterial populations cause dysbiosis, a condition correlated to a wide range of autoimmune, neurological, metabolic, cardiovascular, and respiratory diseases. The lungs have their flora, which are directly related to the gut flora via bidirectional communication allowing the transport of microbial metabolites and toxins produced by intestinal bacteria through the circulation and lymphatic system. This mutual microbial cross-talk communication called the gut-lung axis modulates the immune and inflammatory response to infections. COVID-19 causes dysbiosis, altered intestinal permeability, and bacterial translocation. Dysbiosis, through the gut-lung axis, promotes hyper-inflammation, exacerbates lung damage, and worsens clinical outcomes. Preclinical and clinical studies have shown that probiotics can regulate cytokine secretion, thus affecting both nonspecific and specific immunity. Probiotics act by blocking the virus from invading and proliferating in host cells, by stimulating the immune response, and by suppressing the activation of NLRP3 inflammasome. Herein, we reviewed the evidence from preclinical and clinical studies evaluating the effect of probiotics administration on the immune response to COVID-19 infection by targeting the gut-lung axis microbial cross-talk.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available